Li-Ya Zhou (Liya Zhou)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 12

Top Topics

Atopic Dermatitis

Oxide Nanoparticles

Helicobacter Pylori

Randomized Controlled Trial

Top Venues

Infection and drug resistance

This page only lists publications with an associated author ORCID identifier.

Publications

Yuxin Zhang, Baojun Suo, Xueli Tian, Hua Zhang, Haoping Lu, Xingyu Yao, Cailing Li, Xinlu Ren, Li-Ya Zhou, Zhi-Qiang Song
New regimens as first-line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial. Helicobacter 28 (2) (2023)
Yuxin Zhang, Baojun Suo, Xueli Tian, Hua Zhang, Haoping Lu, Xingyu Yao, Cailing Li, Xinlu Ren, Li-Ya Zhou, Zhi-Qiang Song
New regimens as first-line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial. Helicobacter (2023)
Yuxin Zhang, Baojun Suo, Xueli Tian, Hua Zhang, Haoping Lu, Xingyu Yao, Cailing Li, Xinlu Ren, Li-Ya Zhou, Zhi-Qiang Song
New regimens as first-line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial. Helicobacter 28 (2) (2023)
Xinlu Ren, Yanyan Shi, Baojun Suo, Xingyu Yao, Haoping Lu, Cailing Li, Yuxin Zhang, Li-Ya Zhou, Xueli Tian, Zhi-Qiang Song
Individualized diagnosis and eradication therapy for Helicobacter pylori infection based on gene detection of clarithromycin resistance in stool specimens: A systematic review and meta-analysis. Helicobacter (2023)
Yuxin Zhang, Baojun Suo, Xueli Tian, Hua Zhang, Haoping Lu, Xingyu Yao, Cailing Li, Xinlu Ren, Li-Ya Zhou, Zhi-Qiang Song
New regimens as first-line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial. Helicobacter 28 (2) (2023)
Zhiqiang Song, Ye Chen, Hong Lu, Zhirong Zeng, Wei-Hong Wang, Xiaofeng Liu, Guoxin Zhang, Qin Du, Xingzhou Xia, Changping Li, Shulin Jiang, Ting Wu, Peiyuan Li, Shuixiang He, Yin Zhu, Guiying Zhang, Jianming Xu, Yan Li, Lijuan Huo, Chun-Hui Lan, Yinglei Miao, Haixing Jiang, Ping Chen, Lijun Shi, Biguang Tuo, Dekui Zhang, Kui Jiang, Jiangbin Wang, Ping Yao, Xiaoxi Huang, Shaoqi Yang, Xuehong Wang, Li-Ya Zhou
Diagnosis and treatment of Helicobacter pylori infection by physicians in China: A nationwide cross-sectional study. Helicobacter 27 (3) (2022)
Xue-Li Tian, Bao-Jun Suo, Hua Zhang, Hao-Ping Lu, Cai-Ling Li, Yu-Xin Zhang, Xin-Lu Ren, Xing-Yu Yao, Li-Ya Zhou, Zhi-Qiang Song
Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial. Helicobacter (2022)
Cai Ling Li, Yanyan Shi, Baojun Suo, Xueli Tian, Li-Ya Zhou, Zhiqiang Song
PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis. Helicobacter 26 (4) (2021)
Xingyu Yao, Shiyu Xiao, Li-Ya Zhou
Integrative proteomic and metabolomic analyses reveal the mechanism by which bismuth enables Helicobacter pylori eradication. Helicobacter 26 (6) (2021)
Ziying Yuan, Shiyu Xiao, Sizhu Li, Baojun Suo, Ye Wang, Lingmei Meng, Zuojing Liu, Zhihao Yin, Yan Xue, Li-Ya Zhou
The impact of Helicobacter pylori infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults. Helicobacter 26 (6) (2021)
Rongli Cui, Zhiqiang Song, Baojun Suo, Xueli Tian, Yan Xue, Lingmei Meng, Zhanyue Niu, Zhu Jin, Hejun Zhang, Li-Ya Zhou
Correlation Analysis Among Genotype Resistance, Phenotype Resistance and Eradication Effect of Helicobacter pylori. Infection and drug resistance 14 (2021)
Zhiqiang Song, Li-Ya Zhou, Yan Xue, Baojun Suo, Xueli Tian, Zhanyue Niu
A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial. Helicobacter 25 (6) (2020)